I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) ..:
Karmali, Reem
;
St‐Pierre, Frederique
;
Ma, Shuo
...
eJHaem. 4 (2022) 1 - p. 108-114 , 2022
Link:
https://doi.org/10.1002/jha2.625
RT Journal T1
Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma
UL https://suche.suub.uni-bremen.de/peid=cr-10.1002_jha2.625&Exemplar=1&LAN=DE A1 Karmali, Reem A1 St‐Pierre, Frederique A1 Ma, Shuo A1 Foster, Kelly D. A1 Kaplan, Jason A1 Mi, Xinlei A1 Pro, Barbara A1 Winter, Jane N. A1 Gordon, Leo I. PB Wiley YR 2022 SN 2688-6146 SN 2688-6146 JF eJHaem VO 4 IS 1 SP 108 OP 114 LK http://dx.doi.org/https://doi.org/10.1002/jha2.625 DO https://doi.org/10.1002/jha2.625 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)